RVMD · Revolution Medicines, Inc.
$203.91
+0.28% last session
End-of-day data · close of 2026-09-11
Market cap
$44B
Enterprise value
$41B
Trailing P/E
—
Forward P/E
-34.8
Dividend yield
—
Beta
1.41
Avg volume
2M
Employees
1K
Daily Change %
0.28%
5 Days Change
-1.11%
10 Days Change
1.03%
30 Days Change
1.04%
60 Days Change
11.13%
Month to Day Change
-1.04%
Year to Day Change
160.74%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — RVMD
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-09-10
Latest call per bank · past 12 months
Morgan Stanley
Overweight$255
+25.4% vs priceUBS
Buy$265
+30.3% vs priceRBC Capital
Outperform$251
+23.4% vs priceWells Fargo
Overweight$167
-17.9% vs priceJP Morgan
Overweight$122
-40.0% vs priceGoldman Sachs
Buy$73.00
-64.1% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-10 | Morgan Stanley | Initiates | Overweight | $0.00 → $255 |
| 2026-09-09 | Stifel | Maintains | Buy | $215 → $230 |
| 2026-08-31 | Needham | Maintains | Buy | $240 → $275 |
| 2026-08-28 | UBS | Maintains | Buy | $220 → $265 |
| 2026-08-28 | Guggenheim | Maintains | Buy | $240 → $275 |
| 2026-08-27 | Oppenheimer | Maintains | Outperform | $230 → $260 |
| 2026-08-27 | RBC Capital | Maintains | Outperform | $203 → $251 |
| 2026-08-27 | Wedbush | Maintains | Outperform | $201 → $225 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 49 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 2.9% above the 50-day MA ($198.24).
- Price vs 200-day MA: Trading 49.1% above the 200-day MA ($136.76).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-1.92) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($42.51) and high ($221.15).
RVMD Price Chart
Loading chart for RVMD…
Fundamentals
About Revolution Medicines, Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$130B 14.9% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$82B 5.0% YTD
ARGX
argenx SE
$62B 19.2% YTD
MRNA
Moderna, Inc.
$55B 359.9% YTD
ONC
BeOne Medicines Ltd.
$39B 15.5% YTD
RPRX
Royalty Pharma plc
$34B 59.0% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$33B -35.1% YTD
ROIV
Roivant Sciences Ltd.
$30B 92.7% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.